Platelet polyphosphate and SARS-Cov-2 mRNA-vaccine-induced inflammatory side effects: a pilot study

2.1 Preparation of platelet suspension

The vaccination with mRNA vaccines, BNT162b2 and mRNA-1273, was controlled by the Japanese government and local governments. In principle, the residents were categorized into several groups depending on various factors, such as their age, severity of illness, area of residence, type of occupation, and scheduled for vaccination without or upon their requests and informed when they will be vaccinated.

Regarding to BNT162b2, healthy Japanese subjects [male: n=6 (age: 47−60) or 8 (age: 47−72), female: n=14 (age: 20−57) or 23 (age: 21−66)] who were not receiving continuous medical treatment participated in this study. The age distributions of the sample groups are shown in Figure 1. The female groups (initial dose=36.3±15.0, second dose=36.3±12.3) were significantly younger in average than the male groups (initial dose=56.8±8.8, second dose=56.0±7.8) in both cases.

• Download figure
• Open in new tab

FIGURE 1

Age distribution of male and female groups of (a) the post-initial and (b) the post-second vaccination in the case of BNT162b2. The black and red columns represent male and female groups, respectively. The block dots represent outliers.

When the subjects were available during daytime on weekdays after appropriate intervals (initial dose: 4-10 days, median=8 days, second dose: 4-15 days, median=7 days), blood withdrawal was performed by venipuncture of the median cubital vein using 21G wing needles (NIPRO, Osaka, Japan). Blood was collected into vacutainer A-formulation of acid-citrate-dextrose (ACD-A) glass tubes (BD, Franklin Lakes, NJ, USA). Blood samples were subjected to blood cell count using an automated hematology analyzer (pocH-100i V Diff; Sysmex, Kobe, Japan) and intermittently rotated at 22–25 °C until use.

Prior to centrifugation, an excess amount of ACD-A (0.5 mL) (Terumo, Tokyo, Japan) was added to each blood sample and incubated for 10 min to prevent the unexpected coagulation that is often observed in female samples.¹⁸ Platelets were collected by the dual-spin protocol of pure-PRP preparation (1^st soft spin: 472× g for 10 min, 2^nd hard spin: 578× g for 5 min). The resulting platelet pellets were gently suspended in PBS, incubated for 15 min, and fixed with ThromboFix Platelet Stabilizer (Beckman-Coulter Life Sciences, Indianapolis, IN, USA). The fixed samples were stored at 4 °C for at least 24 h prior to polyP quantification.

The study design and consent forms for all procedures (project identification code: 2019–0423) were approved by the Ethics Committee for Human Participants at the Niigata University School of Medicine (Niigata, Japan) and complied with the Helsinki Declaration of 1964, as revised in 2013.

2.2 Fluorometric measurement of platelet polyphosphate using DAPI

After storage at 4 °C for 24 h, the fixed platelets were centrifuged at 578 × g for 5 min, and the supernatants were carefully aspirated as much as possible. The resulting platelet pellets were gently suspended in Milli-Q water. Platelets were counted using the automated hematology analyzer and adjusted to the appropriate range (<4.5×10⁷/mL) for polyP quantification. 4’,6-Diamidino-2-phenylindole (DAPI) (Dojindo, Kumamoto, Japan) was added to each tube at a concentration of 4 μg/mL and incubated with DAPI for 30 min at 22–25 °C. Fluorescence intensity was measured using a fluorometer (FC-1; Tokai Optical Co., Ltd., Okazaki, Japan) with excitation and emission wavelengths of 425 and 525 nm, respectively.¹⁸

The polyP ratio was calculated in each individual and totaled for statistical analysis.

2.3 Determination of mitochondria activity using cell-counting kit

The number of platelets suspended in PBS were adjusted to the density range of 2.5−5.0×10⁷/100 μL, mixed with 10 μL of cell-counting kit-8 (Dojindo), and incubated for 1 h at 22−25°C. After centrifugation (578 × g, 5 min), the supernatants were subjected to spectrophotometric determination at 450 nm (SmartSpec Plus; Bio-Rad, Hercules, CA, USA).

2.4 Evaluation of side effects based on individual self-declaration

The side effects are listed in Table 1. The perception of vaccine side effects was examined by asking the subjects, “Have you had any of these side effects? Please score each side effect on a scale where 0=not experienced, 1=experienced, and 2=experienced strongly (more important or severe for you). If you took painkillers, please score 1. Also, please mention the number of days the side effects lasted and the frequency of taking medicines against them.”

2.5 Statistical analysis

Each quantification was performed in triplicate. Data are expressed as the mean ± SD in the text and plotted in box plots and scatter plots. The Mann-Whitney U test was performed to compare the two groups (SigmaPlot 13.0; Systat Software, Inc., San Jose, CA, USA). Data for the apparent reduction of platelet polyP levels (<0.9) and the apparent side effect scores (≥10) in individual data were statistically analyzed using Fisher’s exact test. Differences were considered statistically significant at P<0.05.

Linear regression analysis and the calculation of correlation coefficient values were performed using SigmaPlot. Absolute R values ranging from 0.6 to 0.79 and 0.4 to 0.59 were considered a “strong” and “moderate” correlation, respectively. R values of 0.2 to 0.39 and lower than 0.2 indicated a “weak” and “very weak” correlation, respectively.

4.1 Main findings of this study

Prior to designing this study, we hypothesized that if a micro-thrombosis is formed in the peripheral tissue, most probably around the site of vaccine injection, then platelet polyP is released (and intra-platelet polyP levels thereafter decrease) to function as a coagulation factor. However, no symptoms indicating local thrombocytopenia or purpura were observed on visual inspection. Although severe side effects, mainly represented by severe fever, headache, and pain at the injection site, were reported in several female subjects after the second dose, it was speculated that COVID-19 vaccination may not be able to induce platelet-dependent microthrombus formation or internal bleeding.

Interestingly, the vaccination of BNT162b2 significantly reduced platelet polyP levels after the initial dose, while the side effects seemed to be suppressed simultaneously in the younger female group. At present, we have no evidence to suggest how these phenomena are related, that is, a causal relationship or correlation, and further investigation is needed to clarify the involvement of polyP. However, a hypothesis to be considered for further investigation is that the spike protein produced by the mRNA vaccines induces inflammation, which is generally more severe in younger female individuals,²⁰ and that the platelets activated by this inflammation release polyP along with other anti-inflammatory molecules to suppress the inflammation by a “negative feed-back loop.”

The dysfunction of this loop system after the second dose of BNT162b2 may be due to platelet status. Platelets contain various immunoreceptors and continuously scan for areas of injury or inflammation as versatile patrollers.^{21, 22} When platelets recognize intravascular pathogens, they directly limit pathogen growth and indirectly ensure pathogen clearance through the activation of immune cells.^{2, 21, 23} Thus, once the platelet signals are received and taken over by immune cells, inflammation may not be regulated by platelets. However, inflammation becomes more severe, and platelets may become dysfunctional. This scenario could be explained by a “chicken or egg” paradox-like essence introduced by Portier and Campbell that aberrant platelet activation, which could be caused by continuous moderate (or severe) inflammation, can lead to predominantly inflammatory and thrombotic events.²¹

4.2 Factors regulating platelet polyP metabolism

The abovementioned explanation assumes that the reduction of platelet polyP is due to possible polyP release from activated platelets. Before discussing other possible explanations, polyP metabolism in platelets should be confirmed. It is generally accepted that polyP is synthesized from ATP or GTP and degraded by cellular enzymes in bacteria.^{15, 24, 25} In eukaryotes, the mechanism is not yet fully understood; however, polyP is thought to be synthesized and degraded by the same or a similar mechanism. Inorganic phosphate (Pi) is incorporated by a specific transporter into mammalian cells and used for polyP synthesis in mitochondria non-enzymatically.¹³ Although polyP is widely distributed in the cytoplasm and organelles, it is the most condensed and stored in dense granules in platelets and released upon activation.¹³ Thus, it is generally accepted that platelet polyP levels are regulated by three major factors, that is, activation levels, mitochondrial activity, and extracellular Pi levels.

Since platelets of patients with sepsis or cardiac shock similarly have lower mitochondrial nicotinamide adenine dinucleotide dehydrogenase (NADH),²⁶ in this study, we evaluated the activity of NADH using WST-8, a tetrazolium salt that is reduced to soluble formazan²⁷ and found a moderate correlation between the activity of this enzyme and polyP levels. Serum phosphate levels were not examined in this study, but we did not receive any declaration of hyperphosphatemia or hypophosphatemia from individual participants. Taken together, it is most likely that the basal polyP levels depend on mitochondrial activity and influence the polyP reduction induced by platelet activation. Considering that platelet activation is a highly energy-dependent process,²⁸ it is plausible that platelets with higher mitochondrial activity show higher immune responses to release polyP, resulting in polyP reduction.

4.3 Platelet activation by COVID-19 vaccines

In clinical observations, SARS-Cov-2 infection initially produces inflammation, platelet activation, and prominent elevation of fibrinogen and D-dimer.^{6, 7, 9} Subsequently, COVID-19 leads to various levels of thrombotic events and thrombocytopenia.⁶ mRNA vaccines are designed to temporarily provide spike protein at lower levels than those observed in SARS-Cov-2 infection or in DNA vaccines. Thus, even though the initial events induced by SARS-Cov-2 can be reproduced by the mRNA vaccines, theoretically, severe symptoms observed in COVID-19 patients cannot be produced. However, in reality, due to individual differences in immune activity, vaccines sometimes induce thrombotic thrombocytopenia, which is called VITT.^{29, 30} To date, VITT incidence has been recognized to be much lower in the case of mRNA vaccines than in DNA vaccines, such as ChAdOx1 nCov-19 and Ad26.COV2.5, but VITT has been reported in various groups and countries.²⁰

Recently, the mechanism of VITT, mainly represented by heparin-induced thrombocytopenia (HIT), has been proposed.³¹ Platelet factor 4 (PF4) released from activated platelets binds blood heparin to form the complex (PF4-heparin), which binds to IgG antibodies and then binds to platelet FcγRIIa receptors to further activate platelets to induce thrombosis. Interestingly, the authors also mentioned the possibility that polyanions, such as polyP, may bind to PF4 to form the PF4-polyP complex and induce thrombosis. This possibility and the subsequent biological reactions should be further studied.

4.4 Possible platelet activation and thrombosis by polyP

In the earlier subsection, we described the possible anti-inflammatory effects of polyP, which are thought to be mediated through the suppression of the complement system.^{32, 33} However, the “conflicting” possibility that polyP has the potential to induce thrombosis should be noted. Surprisingly, although the chain length of polyP may be a matter for further investigation, it has been reported that polyanions like polyP can form a complex with PF4 and that this complex activates platelets as does the PF4-heparin complex.^{31, 34} Platelets also release anti-inflammatory cytokines, such as IL-4 and IL-10, upon activation,¹ and thus platelet-rich plasma (PRP) has been clinically utilized as an anti-inflammatory agent or a pain-releasing agent.³⁵ At present, it is difficult to predict the risk of PF4-polyP complex-induced thrombosis by the “autocrine” loop or by exposure to bacterial polyP after vaccination.

By applying this possibility to the findings of this study, we interpreted that the biological significance of these conflicting functions is that the unexpected aberrant activation and destruction of platelets and the uncontrolled exacerbation of inflammation and the immune system may be protected by the dual functions of platelets and polyP. Alternatively, especially in the younger female subjects who generally have higher immune activity, when exposed to the pathogens or maintained under inflammatory conditions for a long time (the interval between the initial and second dose in this study ≈3 weeks), platelets may lose the ability to detect pathogens and allow the exacerbation of inflammation, which can be recognized as side effects.

4.5 Limitations

In Japan, the vaccination of medical staff is strictly controlled and scheduled. In addition, our limited capacity to handle samples made it difficult to secure sufficient donor numbers. As a result, we could not expand the sample size to what we originally calculated. Thus, further investigation is needed to reach a definitive conclusion; however, the present findings regarding gender and age differences seem to essentially be consistent with the previous reports of antibody formation^36-38 and, as a pilot study, are worth further investigation.